With its con­tro­ver­sial ad­u­canum­ab ap­proval in hand, Bio­gen gears up for a quick US roll­out

In what will prove to be a con­tro­ver­sial de­ci­sion for years to come, the FDA ear­li­er this week ap­proved Bio­gen’s ad­u­canum­ab for Alzheimer’s dis­ease de­spite some mixed — to say the least — da­ta sup­port­ing its use. But Bio­gen has stayed con­fi­dent it would se­cure that nod, and now all the man­u­fac­tur­ing and lo­gis­tics pre­work the drug­mak­er did to gear up for launch should spell a quick roll­out.

Bio­gen ex­pects to roll out ad­u­canum­ab, mar­ket­ed as Aduhelm, with­in two weeks af­ter plug­ging re­sources in­to sites in Switzer­land and North Car­oli­na in an­tic­i­pa­tion of a launch, the com­pa­ny said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER